GM25456
Fibroblast from Skin, Skin
Description:
RETT SYNDROME; RTT
METHYL-CPG-BINDING PROTEIN 2; MECP2
|
Repository
|
NIGMS Human Genetic Cell Repository
|
| Subcollection |
Heritable Diseases
PIGI Consented Sample |
|
Biopsy Source
|
Skin
|
|
Cell Type
|
Fibroblast
|
|
Tissue Type
|
Skin
|
|
Transformant
|
Untransformed
|
|
Sample Source
|
Fibroblast from Skin, Skin
|
|
Race
|
White
|
|
Ethnicity
|
Not Hispanic/Latino
|
|
Ethnicity
|
Polish/Jewish
|
|
Country of Origin
|
ISRAEL
|
|
Family Member
|
1
|
|
Family History
|
N
|
|
Relation to Proband
|
proband
|
|
Confirmation
|
Clinical summary/Case history
|
|
Species
|
Homo sapiens
|
|
Common Name
|
Human
|
|
Remarks
|
|
| PDL at Freeze |
7.52 |
| Passage Frozen |
3 |
| |
| IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by LINE assay |
| |
| Gene |
MECP2 |
| Chromosomal Location |
Xq28 |
| Allelic Variant 1 |
; RETT SYNDROME |
| Identified Mutation |
c.62+1delGT |
| Remarks |
Clinically affected; onset of symptoms at 18 months of age; diagnosed by Rett Syndrome specialist and pediatrician at 2 years and 7 months of age; fatigue; lack of stamina to stand for long periods of time; pronounced hand dyspraxia and stereotypies (hand wringing, washing, and mouthing); loss of language skills; developmental disturbance with relatively severe mental retardation; EEG is moderately abnormal: ictal events with concomitant theta bursts in the posterior head regions, interictal paracentral epileptiform discharges and posterior background abnormality; good eye contact and normal gait suggesting a milder phenotype; normal biogenic amines (metabolites), folates, neurotransmitters, and pterins in cerebrospinal fluid (CSF); blood test showed a significant decrease of mRNA levels of the two isoforms MECP2A and MECP2B; automated fluorescent dye-terminator sequencing shows the subject has a de novo mutation, c.62+1delGT, at the intron 1 splice site of the MECP2 gene; X chromosome inactivation (XCI) studies on a leukocyte derived DNA sample demonstrated a borderline skewing with preferential inactivation of the paternal allele (68%/32%); a slight insignificant tendency was observed towards overexpression of the maternal chromosome in comparison to the paternal chromosome; uses communication/learning device; treatment and management include physical, occupational, and speech therapies; medications include valproate and clonazepam; subject is referred to by the mutation in the publication by Amir RE et al J Med Genet 2005 (PMID 15689438) and as patient H in the publication by Abuhatzira et al. Hum Genet 2005 (PMID 16133181); lymphoblast is GM25455. |
| Abuhatzira L, Makedonski K, Galil YP, Gak E, Ben Zeev B, Razin A, Shemer R, Splicing mutation associated with Rett syndrome and an experimental approach for genetic diagnosis Human genetics118:91-8 2005 |
| PubMed ID: 16133181 |
| |
| Amir RE, Fang P, Yu Z, Glaze DG, Percy AK, Zoghbi HY, Roa BB, Van den Veyver IB, Mutations in exon 1 of MECP2 are a rare cause of Rett syndrome Journal of medical genetics42:e15 2005 |
| PubMed ID: 15689438 |
| Cumulative PDL at Freeze |
7.52 |
| Passage Frozen |
3 |
| Split Ratio |
1:2 |
| Temperature |
37 C |
| Percent CO2 |
5% |
| Percent O2 |
3% |
| Medium |
Eagle's Minimum Essential Medium with Earle's salts and non-essential amino acids with 2mM L-glutamine or equivalent |
| Serum |
15% fetal bovine serum Not inactivated |
| Supplement |
- |
|
|